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Objective: First, to study how markers of matrix metabolism, inﬂammation markers, and adipokines
relate to (superior) cam deformity and (possible) cam impingement of the hip. Second, to investigate
whether they can identify subjects with cam deformity that are at risk of future hip osteoarthritis (OA).
Method: In a cohort of 1002 subjects (CHECK), (superior) cam deformity was deﬁned by an alpha angle
>60 on anteroposterior pelvic radiographs and (possible) cam impingement by a cam deformity
together with internal hip rotation 20. Hip OA at 5-year follow-up was deﬁned by Kellgren and
Lawrence grade 2 or total hip replacement.
Results: Subjects with (superior) cam deformity and (possible) cam impingement showed lower levels of
bone turnover markers (uCTX-I, uNTX-I, sPINP, sOC) than those without. Cam deformity was positively
associated with future hip OA, but associations were weaker at high levels of bone turnover. sCOMP and
sHA levels were higher in subjects with cam deformity, while other cartilage and synovium markers
were not. Some markers of inﬂammation (pLeptin, pAdiponectin, and erythrocyte sedimentation rate)
were lower in presence of cam deformity and cam impingement, but high-sensitivity C-reactive protein
was not. Most associations depended largely on gender differences.
Conclusion: Bone metabolism may be relevant in the pathogenesis of (superior) cam deformity and in
the development of (superior) cam deformity into hip OA. Subjects with cam deformity and cam
impingement surprisingly showed lower levels of inﬂammation markers and adipokines. Associations of
cartilage turnover markers with cam deformity and cam impingement were less obvious.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) should no longer be considered a single
disease entity, but rather a heterogeneous disease with varying
features between subtypes1,2. In the past decade, it has become
apparent that in particular subgroups of patients abnormal hip
morphology is an important factor in the development of hip OA3.
Especially the presence of cam deformity, characterized by extrao: W.E. van Spil, University
l: 31-88-75-573-57;
W.E. van Spil), r.agricola@
.W. Drossaers-Bakker), h.h.
trecht.nl (F.P.J.G. Lafeber).
ternational. Published by Elsevier Lbone formation at the anterolateral femoral headeneck junction,
was found to be strongly associated with future development of hip
OA4.
Still, most individuals with cam deformity will not develop OA.
Reported positive predictive values of cam deformity to determine
hip OA vary between 6% and 25% and negative predictive values
between 98% and 99%5. This suggests that although cam deformity
is a risk factor for hip OA, additional factors (e.g., sport activities) do
inﬂuence the probability of developing OA. As the pathophysiology
of cam impingement includes gradual changes in cartilage and
subchondral bone structure6,7, serum and urinary biochemical
markers of matrix metabolism from these tissues might help in
identifying those particular individuals with cam deformity that
will develop hip OA.td. All rights reserved.
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inﬂammation do occur in cam impingement. Plasma levels of
cartilage oligomeric matrix protein (COMP) and C-reactive protein
(CRP) were increased in athletes with femoroacetabular impinge-
ment (FAI; cam-type, pincer-type, or mixed) as compared to control
athletes8. In line with these ﬁndings, gene expression proﬁles
suggested an heightened metabolic state in cartilage of the
impingement zone as compared with healthy and osteoarthritic
cartilage6. However, to the best of our knowledge, epidemiological
studies on this subject are currently unavailable. Moreover, no
studies have tried to stratify subjects with cam deformity using
biochemical markers in order to determine their risk of future hip
OA.
In the current study, wemeasured baseline levels of biochemical
markers of matrix metabolism, inﬂammation markers, and adipo-
kines in CHECK (Cohort Hip and Cohort Knee), a large prospective
cohort study of 1002 subjects with early-stage knee and/or hip
symptoms. Our ﬁrst aim was to examine cross-sectional associa-
tions of these levels with presence of (superior) cam deformity and
(possible) cam impingement, the latter being a combination of a
radiographic cam deformity together with clinical signs of
impingement. This might elucidate aspects of the pathogenesis of
cam deformity and impingement. Our second aim was to investi-
gate whether these levels could predict which hips with a cam
deformity continued to develop hip OA in the next ﬁve years.
Method
Cohort characteristics
The current study was performed using 5-year data from
CHECK, a cohort of subjects age 45e65 years, with pain and/or
stiffness of one or both knee(s) and/or hip(s) at baseline, that at the
time of inclusion had never or not longer than 6 months ago visited
a general physician for these complaints for the ﬁrst time9. Subjects
with any other pathological knee and/or hip condition(s) that could
explain these symptoms were excluded. For the hip these alterna-
tive conditions included other rheumatic diseases, trauma,
dysplasia, Perthes disease, subluxation, osteochondritis dissecans,
fracture, previous hip surgery, acetabular protrusion, Kellgren and
Lawrence (K&L) grade 4 or previous joint replacement, and subjects
only having symptoms of bursitis or tendinitis.
Biochemical marker and adipokine assessment
Biochemical marker, high-sensitivity C-reactive protein (hsCRP),
erythrocyte sedimentation rate (ESR), and adipokine levels were
assessed in serum, plasma, and second morning void urine sam-
ples, collected in a non-fasted state, between 8 and 12 AM.
Biochemical markers and adipokines were assessed by enzyme-
linked immunosorbent assay or radioactive immunoassay, ac-
cording to manufacturer instructions, as was described previ-
ously10. Intra-plate, inter-plate, and between-day coefﬁcients of
variation (standard deviation/mean*100%) were as follows: C-ter-
minal telopeptide of collagen type II (CTX-II; Urine Cartilaps EIA,
Immunodiagnostic systems Ltd., Boldon, UK): 10.0%, 9.3%, and
12.4%. Cartilage oligomeric matrix protein (Anamar Med AB,
G€oteborg, Sweden): 5.0%, 4.0%, and 4.2%. N-terminal propeptide of
procollagen type IIA (PIIANP; Millipore Corp, Billerica, MA, US):
15.8%, 7.0%, and 15.7%. Chondroitin sulphate 846 (CS846; IBEX,
Montreal, Canada): 21.5%, 16.9%, and 15.3%. C-terminal telopeptide
of collagen type I (CTX-I, Urine Crosslaps EIA, Immunodiagnostic
systems Ltd., Boldon, UK): 9.7%, 6.1%, and 2.7%. N-terminal telo-
peptide of collagen type I (NTX-I, OSTEOMARKNTx Urine,Wampole
laboratories, Princeton, US): 14.9%, 6.6%, and 10.7%. N-terminalpropeptide of procollagen type I (PINP, UniQ, Orion Diagnostica,
Espoo, Finland): 4.4%, 4.5%, and 6.2%. Osteocalcin (OC, N-MID
Osteocalcin ELISA, Immunodiagnostic systems Ltd., Boldon, UK):
3.4%, 4.1%, and 4.3%. Hyaluronic acid (HA; Corgenix Inc, West-
minster, CO, US): 15.1%, 13.0%, and 17.3%. N-terminal propeptide of
procollagen type III (PIIINP; UniQ, Orion Diagnostica, Espoo,
Finland): 5.4%, 3.2%, and 7.2%. Leptin (BioVendor, Modrice, Czech
Republic): 7.8, 5.7, and 7.0%. Adiponectin (BioVendor, Modrice,
Czech Republic): 18.9, 14.3, and 9.0%. Resistin (BioVendor, Modrice,
Czech Republic): 7.1, 3.9, and 2.5%. Urinary biomarker levels were
adjusted for urinary creatinine concentrations (automated kinetic
assay, UniCel® DxC 800 Synchron® Clinical System, Beckman
Coulter). Serum levels of hsCRP were assessed by an automated
nephelometric assay (BN™ II analyzer, Siemens, routine clinical
chemistry laboratory, University Medical Center Utrecht, Utrecht,
The Netherlands). ESR was assessed according to clinical practice in
each of the ten participating medical centers.
Radiographic and clinical assessments
Weight-bearing anteroposterior pelvic radiographs were ob-
tained at baseline and after 5 years, according to standardized
protocols. Feet were positioned such that the medial side of the
distal part of the ﬁrst phalanx touched. Awedge was used to assure
15 internal rotation. The tube to ﬁlm distance was 100 cm and the
beam was centered at the top of the pubic symphysis. On these
radiographs, the shape of the proximal femur was then outlined
using statistical shape modelling (SSM) software (ASM tool kit,
Manchester University, Manchester, UK) so that the alpha angle
could be calculated automatically, as was all explained in more
detail before4. The alpha angle measures the extent to which the
femoral head deviates from spherical, as is shown in Fig. 1, and is
the most frequently applied parameter for quantifying cam defor-
mity. Osteophytes were excluded while placing the SSM point set
from which the alpha angle was quantiﬁed.
In the current study, both cam deformity and cam impingement
were investigated. Presence of radiographic (superior) cam defor-
mity was deﬁned by an alpha angle threshold of >60 on the
anteroposterior radiographs, as was recently validated in the
CHECK and Chingford cohorts11. (Possible) Cam impingement was
deﬁned by the presence of cam deformity together with limited
internal hip rotation of20 (as measured in 90 of hip ﬂexion), the
latter being a clinical sign suggestive of cam impingement12.
In addition, all anteroposterior pelvic radiographs were scored
for hip OA according to the K&L classiﬁcation system (grade 0e4)13.
Presence of hip OA at 5-year follow-up was deﬁned by K&L grade
2 changes or total hip replacement. Radiographs of tibiofemoral
knee joints were made in a weight-bearing posteroanterior view,
semiﬂexed (7e10 degrees) and were also scored for knee OA ac-
cording to the K&L classiﬁcation system, as was explained in more
detail before14.
Knee and hip pain were classiﬁed as either absent or present
according to the history of the patient that was obtained by an
experienced rheumatologist.
Statistical analysis
In all analyses, hip parameters were included for each hip
individually. To take into account the probable dependence be-
tween the two hips in one subject we used generalized estimation
equation analysis. Logistic models for binary outcomes were
created, introducing continuous variables as covariates (age; body
mass index; biochemical marker and adipokine levels) and discrete
variables as factors (gender; knee pain absent, unilateral, or bilat-
eral; knee OA absent, unilateral, or bilateral; hip OA absent or
Fig. 1. The best ﬁtting circle around the femoral head and the positioning of the two lines to calculate the alpha angle were automatically determined by Matlab using the SSM point
set (green dots). Panel A shows an alpha angle of 51, indicating a spherical femoral head. Panel B shows an alpha angle of 95 , indicating (superior) cam deformity.
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Biochemical marker and adipokine levels and body mass index
(BMI) were logarithmically transformed to obtain normal
distribution.
To study the inﬂuence of baseline marker and adipokine levels
on the association between cam deformity and future hip OA we
looked for interaction. Statistically signiﬁcant interaction between
presence of cam deformity and marker levels at baseline in their
association with future hip OA indicates that the strength of the
association of cam deformity with future hip OA depends on the
level of that marker. The number of subjects with cam impinge-
ment was judged too low to study interaction with marker levels
effectively in subjects with cam impingement only.
To facilitate comparison of effect sizes between markers and
adipokines, all marker and adipokine levels were standardized into
Z-scores so that for each of them mean ¼ 0 and standard
deviation ¼ 1. This way, odds ratios are independent of the units of
measurement and do represent the change in odds with every
standard deviation increase of the marker or adipokine concerned.
All statistical analyses were performed using SPSS, version 22.0.
Statistical signiﬁcance was deﬁned as P < 0.05, and as P < 0.100 for
interaction terms.
Results
Data acquisition and subject characteristics
A ﬂow diagram of the selection of subjects with complete
radiographic, demographic, and biochemical data is shown in Fig. 2.
Baseline characteristics for those subjects for whom data were and
were not available are demonstrated in Table I. Although some-
times statistically signiﬁcant, differences were judged not to be
clinically relevant.
Cross-sectional associations of biochemical marker levels with cam
deformity of the hip
Biochemical markers of bone metabolism consistently showed
negative associations with presence of (superior) cam deformity, as
is shown in Table II, column A and Fig. 3. For sPINP this association
disappeared after adjustment for concurrent knee and hip OA (K&Lgrade 0 or 1), but persisted for the other markers (Table II, column
B). The associations of uCTX-I and uNTX-I disappeared after
adjustment for demographics, gender in particular. The association
of sOC turned less signiﬁcant after adjustment for demographics.
Again, gender appeared to be the most relevant demographic.
(Table II, column C).
sCOMP was positively associated with presence of cam defor-
mity, also after adjustment for concurrent knee and hip OA (Table II,
columns A and B and Fig. 3). The association disappeared only after
adjustment for demographics, gender being the most important
(Table II, column C). None of the other markers of cartilage meta-
bolism were associated with cam deformity.
sHA showed a positive association with presence of cam
deformity (Table II, column A and Fig. 3) that disappeared only after
adjustment for demographics (Table II, column C). In contrast, ESR
showed a negative association with presence of cam deformity
(Table II, column A and Fig. 3) that disappeared after adjustment for
demographics and for gender in particular (Table II, column C).
hsCRP did not show any association with presence of cam
deformity.
Among the adipokines, pLeptin and pAdiponectin showed
negative associations with presence of cam deformity (Table II,
column A and Fig. 3) that disappeared after adjustment for de-
mographics, gender being one important demographic (Table II,
column C). pResistin was not associated with cam deformity.Cross-sectional associations of biochemical marker levels with cam
impingement of the hip
Biochemical markers of bone metabolism consistently showed
negative associations with presence of (possible) cam impinge-
ment, reaching statistical signiﬁcance for uCTX-I, sPINP, and sOC
(Table III, column A). The association of sOC already disappeared
after adjustment for concurrent knee and hip OA (Table III, column
B). For uCTX-I and sPINP adjustment for BMI and age did not in-
ﬂuence associations so much, but adjustment for gender made
them disappear (Table III, column C).
None of the markers of cartilage metabolism showed a statis-
tically signiﬁcant association with presence of cam impingement
(Table III). Among the markers of synovial metabolism, sHA did
show a positive association with presence of cam impingement
Fig. 2. Flow diagram showing the selection of subjects with complete data on hip and
knee parameters, demographics, and biochemical markers.
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knee and hip parameters (Table III, column B).
hsCRP levels did not show associations with presence of cam
impingement, but ESR did (Table III, column A). Surprisingly, the
association of ESR with cam impingement was negative. Again, the
negative association of ESR with cam impingement did only
disappear after adjustment for gender but not when adjusted for
the other demographics (Table III, column C).pLeptin and pAdiponectin did both show negative associations
with the presence of cam deformity (Table III, column A). The as-
sociation of pLeptin decreased substantially after adjustment for
gender (P ¼ 0.044), while it disappeared for pAdiponectin after
adjustment for gender (Table III, column C). pResistin did not show
any association with presence of cam deformity, except for one
positive association after adjustment for concurrent knee and hip
OA that disappeared after adjustment for demographics.
Interaction of marker and adipokine levels in the association
between cam deformity and future hip OA
uNTX-I, sPINP, and sPIIINP each showed statistically signiﬁcant,
negative interaction with (superior) cam deformity in its associa-
tion with future hip OA (P ¼ 0.089 for uNTX-I, P ¼ 0.077 for sPINP,
and P ¼ 0.016 for sPIIINP, data not shown). For these markers, the
association between presence of cam deformity and future hip OA
was calculated per tertile of each of the markers (Fig. 4). For each of
the markers, the association of cam deformity with future hip OA
disappeared in subjects in the third, highest tertile.
Discussion
This is the ﬁrst epidemiological study investigating associations
of systemic levels of biochemical markers of matrix metabolism,
inﬂammation markers, and adipokines with (superior) cam defor-
mity and (possible) cam impingement and to relate them to the
association between (superior) cam deformity and future hip OA.
Higher levels of bone metabolism, as quantiﬁed by biochemical
markers, appeared to be negatively associated with presence of
cam deformity and cam impingement. sHA showed a positive as-
sociationwith cam deformity and cam impingement. ESR showed a
negative association with presence of cam deformity and cam
impingement. Most markers of cartilage metabolism did not show
any association with cam deformity or cam impingement, except
for one positive association of sCOMP with presence of cam
deformity. pLeptin and pAdiponectin showed negative associations
with cam deformity and cam impingement. The vast majority of
these associations were highly dependent on differences between
genders. uNTX-I, sPINP, and sPIIINP each showed statistically sig-
niﬁcant interaction with the association between cam deformity
and future hip OA. It appeared that the association of cam defor-
mity with future hip OA disappeared at higher baseline levels of
these markers.
The negative associations of markers of bone metabolism with
presence of cam deformity and cam impingement can be inter-
preted in several ways. Similar considerations apply to the negative
interaction of uNTX-I and sPINP with the association of cam
deformity with future hip OA. First, when these serum and urinary
marker levels would relate to local joint conditions, our ﬁndings
indicate that bone turnover is decreased in hips with cam defor-
mity and that this decreased bone turnover may play a role in the
development of cam deformity into hip OA. Whether these lower
levels of bone turnover translate into either decreased or increased
bone density does not become clear from our study. However, one
small study has demonstrated higher subchondral bone density in
the cam deformity as compared to the peripheral region of the
femoral head in control subjects7. Interestingly, the same study also
showed that the subchondral bone density of the cam deformity
was lower in symptomatic hips than in asymptomatic hips with
cam deformity. The latter might correspond to the negative inter-
action of uNTX-I and sPINP in the association of cam deformity with
future hip OA. Second, whenmarker levels would relate to systemic
bone metabolism, our ﬁndings indicate that higher levels of sys-
temic bone metabolism might protect against development of cam
Table I
Comparison of demographics and biochemical marker levels between subjects for whom hip and knee parameters were and were not available. Data are presented as number
per category for discrete variables, as mean ± standard deviation for normally distributed continuous variables, and as median (25%e75% percentiles) for non-normally
distributed variables. P values for the comparison between discrete variables were calculated by chi square testing, P values for the comparison between continuous vari-
ables were calculated by unpaired T testing
Hip and knee data available N ¼ 1583 Hip and knee data unavailable N ¼ 421 P
Hip K&L grade 1205/378
76.1/23.9
NA N 0/1
% 0/1
Gender 325/1258
20.5/79.5
95/326
22.6/77.4
N male/female
% male/female
0.362
Age 55.8 ± 5.2 56.2 ± 5.4 Years 0.185
BMI 25.4 (23.4e28.4) 25.7 (23.2e28.2) kg/m2 0.459
Hip OA at 5-year follow-up 1464/114/5
92.8/7.2
130/16/146
89.0/11.0
N absent/present/missing
% absent/present
0.102
uCTX-I 153 (103e226) 142 (91e219) mg/mmol 0.297
uNTX-I 37.4 (27.8e51.0) 34.9 (26.6e48.0) BCE/mmol 0.030
sPINP 46.7 (32.4e55.9) 41.6 (31.1e54.6) ng/ml 0.320
sOC 13.0 (10.5e16.6) 13.1 (10.1e16.6) ng/ml 0.416
uCTX-II 195 (131e285) 189 (134e269) ng/mmol 0.655
sCOMP 8.4 (7.2e9.8) 8.6 (7.2e10.3) U/l 0.120
sPIIANP 1385 (1077e1762) 1392 (1135e1829) ng/ml 0.129
sCS846 69.7 (53.8e87.5) 75.5 (59.6e91.0) ng/mmol 0.027
sHA 25.7 (16.7e41.3) 31.1 (10.1e16.6) ng/ml <0.001
sPIIINP 4.1 (3.5e4.9) 4.2 (3.6e5.1) ng/ml 0.099
hsCRP 1.4 (0.7e3.3) 1.6 (0.7e3.2) mg/l 0.146
ESR 7.5 (5e13) 7 (5e13) mm/hr 0.972
pLeptin 11.7 (6.3e21.7) 11.8 (6.4e21.4) ng/ml 0.736
pAdiponectin 9.8 (7.3e14.3) 10.1 (7.1e14.6) mg/ml 0.754
pResistin 3.5 (3.0e4.3) 3.5 (2.9e4.2) ng/ml 0.848
P values are in bold for statistically signiﬁcant differences (P < 0.05).
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already develops during skeletal maturation15. Similarly, higher
levels of systemic bone metabolism might protect against devel-
opment of cam deformity into hip OA. The only data that may argue
against this hypothesis comes from the aforementioned study onTable II
Comparison of biochemical marker and adipokine levels between subjects with and with
Column A represents unadjusted associations, column B shows associations after adjustm
column C shows associations after further adjustment for age, gender, and BMI. Odds rat
deviation increase in the predictor (i.e., biochemical marker or adipokine levels). For tho
disappeared after adjusting for all demographics together, adjustment for gender only is
Outcome: a angle >60 Adjusted fo
Predictors A) Unadjusted B) Knee and
OR per SD P OR per SD
uCTX-I 0.750 (0.630e0.892) 0.001 0.765 (0.64
uNTX-I 0.764 (0.616e0.947) 0.014 0.780 (0.62
sPINP 0.804 (0.675e0.958) 0.014 0.854 (0.71
sOC 0.728 (0.599e0.883) 0.001 0.769 (0.63
uCTX-II 1.000 (0.840e1.190) 0.998 0.958 (0.79
sCOMP 1.441 (1.174e1.768) <0.001 1.401 (1.13
sPIIANP 1.034 (0.850e1.257) 0.742 0.986 (0.81
sCS846 1.069 (0.896e1.276) 0.457 1.030 (0.85
sHA 1.402 (1.146e1.716) 0.001 1.276 (1.03
sPIIINP 1.182 (0.974e1.433) 0.090 1.209 (0.96
hsCRP 1.140 (0.954e1.362) 0.150 1.147 (0.95
ESR 0.700 (0.578e0.849) <0.001 0.705 (0.58
pLeptin 0.621 (0.503e0.769) <0.001 0.651 (0.52
pAdiponectin 0.690 (0.549e0.868) 0.001 0.725 (0.57
pResistin 1.113 (0.883e1.402) 0.365 1.142 (0.90
P values are in bold for statistically signiﬁcant differences (P < 0.05).subchondral bone density in hips with and without cam type
deformity. It showed similar subchondral bone density in the pe-
ripheral bearing surface of the femoral head between hips with and
without came type deformity, possibly indicating that systemic
bone density is not different7. Third, the associations between boneout (superior) cam deformity of the hip, deﬁned as a radiographic alpha angle >60 .
ent for concurrent knee pain and radiographic K&L grades for knees and hip, and
ios represent the change of the odds for a hip of having cam deformity per standard
se markers and adipokines for which associations with presence of cam deformity
also shown
r
hip OA C) þ Demographics
P OR per SD P
7e0.906) 0.002 0.936 (0.750e1.168) 0.557
Gender only 0.919 (0.751e1.124) 0.411
7e0.971) 0.027 0.997 (0.786e1.265) 0.980
Gender only 1.002 (0.795e1.262) 0.987
5e1.021) 0.084 0.968 (0.771e1.214) 0.073
4e0.928) 0.006 0.800 (0.647e0.988) 0.038
Gender only 0.804 (0.658e0.983) 0.034
5e1.154) 0.648 1.127 (0.875e1.451) 0.354
8e1.725) 0.001 1.177 (0.931e1.487) 0.172
Gender only 1.234 (0.989e1.537) 0.063
0e1.201) 0.888 1.053 (0.861e1.289) 0.615
0e1.251) 0.758 1.063 (0.853e1.326) 0.585
7e1.573) 0.022 1.134 (0.873e1.474) 0.346
Gender only 1.206 (0.956e1.519) 0.114
Age only 1.220 (0.973e1.531) 0.085
BMI only 1.246 (1.006e1.543) 0.043
9e1.508) 0.093 1.138 (0.884e1.462) 0.315
8e1.374) 0.136 1.194 (0.956e1.489) 0.118
6e0.848) <0.001 0.936 (0.749e1.171) 0.564
Gender only 0.931 (0.756e1.147) 0.502
5e0.807) <0.001 0.783 (0.543e1.129) 0.189
Gender only 1.047 (0.805e1.362) 0.733
5e0.915) 0.007 1.005 (0.770e1.310) 0.972
Gender only 0.970 (0.750e1.256) 0.822
8e1.438) 0.258 1.160 (0.903e1.489) 0.247
Fig. 3. Boxplot graphs demonstrating statistically signiﬁcantly different biochemical marker, inﬂammation markers, and adipokine levels between subjects with and without
(superior) cam type deformity of the hip. Whiskers represent minimum and maximum values. P values correspond to those in Table II, column A.
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ment may be non-causal and rather reﬂect the lower incidence of
cam deformity in women from another cause (i.e., confounding).
The negative association of ESR with presence of cam deformity
and/or cam impingement was rather surprising. It seems counter-
intuitive that inﬂammation may protect against development of
cam deformity and/or cam impingement or that presence of cam
deformity and/or impingement would decrease inﬂammation. The
association that we found is unlikely to be causal, but may rather
represent confounding by gender differences from other causes.
Furthermore, our ﬁnding contradicts with a small study showing
increased plasma CRP levels in athletes with FAI (cam-type, pincer-
type, or mixed) as compared to control athletes8. We were not able
to demonstrate different hsCRP levels between subjects with and
without cam deformity or cam impingement. The difference be-
tween our study and the athlete study may reﬂect a difference
between cohorts (athletes age 18e40 years vs subjects selected
from the general population age 45e65 years).
Previous studies have demonstrated increased metabolic rates
in cartilage from the impingement zone in subjects with FAI6,8. In
our study, this was possibly reﬂected in higher sCOMP levels in
subjects with cam deformity, but not in different levels of the othercartilage markers. None of the cartilage markers showed differ-
ences between hips with and without cam impingement. These
observations lead to a number of considerations. First, the intra-
articular cartilage changes that occur in hips with cam impinge-
ment may not be large enough to overwhelm the noise that results
from cartilage marker variability from other sources (e.g., release
from other joints, diurnal variability)16,17. Second, it might be that
cam impingement results in so called carpet lesions, in which the
cartilage is delaminated from the subchondral bone, rather than
actual cartilage damage18. Third, sCOMP might be a marker of sy-
novial metabolism rather than of cartilage degradation, in analogy
with sHA. Fourth, the timing of the marker assessment in relation
to the development of the cam deformity and cam impingement
may not have been optimal. These considerations may also explain
why cartilagemarkers did not show interaction in the association of
cam deformity with future hip OA. Longitudinal cartilage marker
data would have been valuable in this respect, but were not
available.
Plasma leptin and adiponectin levels were negatively associated
with the presence of cam deformity and cam impingement. The
negative association of the generally considered pro-inﬂammatory
leptin19 with presence of cam impingement seems counterintuitive.
Table III
Comparison of biochemical marker and adipokine levels between subjects with and without (possible) cam impingement of the hip, deﬁned as both reduced internal rotation
(20) and a radiographic alpha angle >60 . Column A represents unadjusted associations, column B shows associations after adjustment for concurrent knee pain and
radiographic K&L grades for knees and hip, and column C shows associations after further adjustment for age, gender, and BMI. Odds ratios represent the change of the odds for
a hip of having cam impingement per standard deviation increase in the predictor (i.e., biochemical marker or adipokine levels). For those markers and adipokines for which
associations with presence of cam impingement disappeared after adjusting for all demographics together, adjustment for gender only is also shown
Outcome: a angle >60 and internal rotation 20 Adjusted for
A) Unadjusted B) Knee and hip OA C) þ Demographics
OR per SD P OR per SD P OR per SD P
uCTX-I 0.715 (0.568e0.899) 0.004 0.696 (0.542e0.893) 0.004 0.875 (0.592e1.294) 0.505
Gender only 0.859 (0.608e1.215) 0.391
uNTX-I 0.782 (0.546e1.120) 0.180 0.789 (0.544e1.143) 0.210 1.097 (0.724e1.662) 0.662
sPINP 0.658 (0.498e0.869) 0.003 0.672 (0.484e0.933) 0.018 0.743 (0.492e1.122) 0.157
Gender only 0.760 (0.513e1.129) 0.174
sOC 0.783 (0.636e0.966) 0.022 0.843 (0.668e1.062) 0.147 0.906 (0.613e1.338) 0.619
uCTX-II 0.961 (0.759e1.217) 0.739 0.875 (0.677e1.130) 0.305 1.146 (0.763e1.719) 0.512
sCOMP 1.140 (0.795e1.636) 0.476 1.028 (0.737e1.435) 0.869 1.281 (0.978e1.677) 0.072
sPIIANP 0.787 (0.605e1.026) 0.078 0.794 (0.592e1.065) 0.124 0.794 (0.595e1.059) 0.116
sCS846 0.811 (0.573e1.148) 0.238 0.757 (0.525e1.093) 0.138 0.737 (0.488e1.113) 0.147
sHA 1.548 (1.127e2.125) 0.007 1.249 (0.908e1.718) 0.173 1.077 (0.700e1.655) 0.736
sPIIINP 0.903 (0.738e1.106) 0.324 0.860 (0.666e1.110) 0.246 0.837 (0.635e1.102) 0.205
hsCRP 1.068 (0.787e1.451) 0.671 1.081 (0.814e1.436) 0.590 1.265 (0.895e1.788) 0.183
ESR 0.634 (0.449e0.893) 0.009 0.644 (0.464e0.893) 0.008 0.960 (0.663e1.388) 0.826
Gender only 0.913 (0.646e1.290) 0.607
pLeptin 0.441 (0.326e0.598) <0.001 0.482 (0.349e0.665) <0.001 0.667 (0.426e1.044) 0.077
Gender only 0.748 (0.497e1.125) 0.163
pAdiponectin 0.572 (0.386e0.847) 0.003 0.606 (0.404e0.909) 0.016 0.813 (0.498e1.327) 0.409
Gender only 0.868 (0.536e1.408) 0.567
pResistin 1.261 (0.935e1.701) 0.129 1.302 (1.001e1.696) 0.049 1.384 (0.995e1.923) 0.054
Gender only 1.387 (1.009e1.906) 0.044
Age only 1.298 (1.007e1.672) 0.044
BMI only 1.281 (0.968e1.699) 0.084
P values are in bold for statistically signiﬁcant differences (P < 0.05).
W.E. van Spil et al. / Osteoarthritis and Cartilage 23 (2015) 1897e1905 1903The role of adiponectin in inﬂammation, either pro-inﬂammatory or
anti-inﬂammatory, is less clear and may differ between diseases and
conditions20,21. Another unexpected ﬁnding was that the negative
associations of these adipokines with presence of cam deformity
were not related to BMI. The associations did only disappear after
adjustment for gender. The different adipokine levels between men
and women probably result in part from different fat tissue distri-
bution between genders (subcutaneous, intra-abdominal etc)22.
It is important to bear in mind that the radiographic presence of
a cam deformity does not equal cam-type FAI or cam impingement,
in which there is repetitive abnormal contact between the cam
deformity and acetabulum23. However, because of the dynamicFig. 4. Association of presence of (superior) cam deformity of the hip at baseline with hi
presence of cam deformity, associations between cam deformity and future hip OAwere calc
the interaction. The vertical dotted line indicates OR ¼ 1. Error bars represent 95% conﬁdennature of impingement it is impossible to deﬁne if and when cam
impingement truly occurs, except in an operative setting. Though,
the combination of a cam deformity and limited internal hip rota-
tion, which is a clinical sign of cam impingement, has previously
shown to better predict the development of hip OA than cam
deformity only4. However, additional factors such as the type and
intensity of exercise also determinewhether cam impingement will
actually occur.
As any other study, our study has both its strengths and weak-
nesses. Obvious strengths are the large size of the cohort and the
large number of biochemical markers, inﬂammation markers, and
adipokines that were available. One obvious limitation is the lack ofp OA at ﬁve years. Based on statistically signiﬁcant interaction between markers and
ulated per tertile of each of the markers. P values represent the statistical signiﬁcance of
ce intervals.
W.E. van Spil et al. / Osteoarthritis and Cartilage 23 (2015) 1897e19051904longitudinal data on biochemical markers, inﬂammation markers,
and adipokines. Although the cohort was large, only a limited
number of subjects showed (possible) cam impingement (both
radiographic and clinical signs of cam FAI) and the outcome of hip
OA at 5-year follow-up. One general limitation of most cohort
studies is that they can only suggest but not prove causal relations.
Further, the use of anteroposterior pelvic radiographs only will
have underestimated the true prevalence of cam deformities as
only the more laterally located (superior) cam deformities can be
quantiﬁed. Nevertheless, the presence of a cam deformity on
anteroposterior pelvic radiographs has previously shown to be a
good predictor of future hip OA5.
Concluding, our study suggests more or less consistent associ-
ations of markers of matrix metabolism, inﬂammation markers,
and adipokines with (superior) cam deformity and (possible) cam
impingement. Most of these associations were largely dependent
on gender. Especially the potential role of bone metabolism in the
association between cam deformity and future hip OA urges further
investigation.
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